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Abstract
Radiation related effects in children and adults limit the delivery of effective radiation doses and
result in long-term morbidity affecting function and quality of life. Improvements in our
understanding of the etiology and biology of these effects, including the influence of clinical
variables, dosimetric factors, and the underlying biologic processes has made treatment safer and
more efficacious. However, the approach to studying and understanding these effects differs between
children and adults. By using the pulmonary and skeletal organ systems as examples, comparisons
are made across the age spectrum for radiation related effects including pneumonitis, pulmonary
fibrosis, osteonecrosis and fracture. Methods for dosimetric analysis, incorporation of imaging and
biology as well a length of follow-up are compared, contrasted and discussed for both organ systems
in children and adults. Better understanding of each age specific approach and how it differs may
improve our ability to study late effects of radiation across the ages
INTRODUCTION
Radiation therapy (RT)-induced acute and late normal tissue effects limit the delivery of safe,
therapeutically-optimal RT doses for a variety of pediatric and adult cancers. Our incomplete
understanding of how to limit these normal tissue effects, while still controlling the cancer, is
a major clinical problem. For example, in adults, we are often unable to deliver sterilizing doses
of RT for cancers of the lung and prostate. In children, we accept that there are long-term
chronic treatment effects from RT. While we know that RT is an effective anti-cancer agent,
the current paradigm is one of ‘radiation avoidance’ in treatment and clinical trial design.
Modern RT planning and delivery tools (e.g. conformal and intensity modulated radiation
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therapy) increase our ability to study and understand the dose/volume dependence of RT-
induced normal tissue effects. We herein discuss some of the common normal tissue effects in
adults and children, highlighting some of the differences and similarities in how these issues
are addressed across the age spectrum. Differences in the timing to occurrence and the severity
of RT-related treatment effects between childhood and adult cancer patients influence both the
strategies for RT (including both technique and dose), and how the effects of RT are studied
across the age spectrum. Understanding these differences, why they exist, and what can be
derived from each approach, will foster further progress in improving late normal-tissue
outcomes for our patients.
General differences in RT delivery and treatment effects between children and adults
All organ systems have specific responses to RT, and their propensity to RT-induced injury is
variously similar or different across the age spectrum. Several general issues, unrelated to the
nuances and characteristics of individual normal tissues, exist across these groups.
Fraction size in the era of intensity modulated radiation therapy—RT delivered to
both children and adults typically uses multiple treatment fields to create a conformal dose
distribution around the tumor volume. The adjacent normal tissues are usually exposed to
fraction sizes lower than those delivered to the target tissues (e.g. < 1.8 Gy per day), based on
the number of beams. Across all age groups, fraction size has historically been a strong
predictor of late effects when total dose for that normal tissue is held constant. Thus, this lower
dose per fraction tends to lessen late effects in surrounding normal tissues. However, since the
total doses in adults are often higher than in children (e.g. ≈70 Gy for adult thoracic or head
and neck sites vs. 45 – 55.8 Gy for many pediatric diseases), this sparing of surrounding tissues
may be less marked. Conversely, some late effects in children tend to occur at lower doses (e.g.
growth disturbance) and are less well spared with lower fraction sizes (e.g. cancer induction).
Classification of Endpoints for Late Effects—Events are classified differently in
children and adults. In adults, effects are often considered binary (e.g. present or absent) and
it is common to consider a relatively short time interval for evaluation of late effects (e.g. 6-12
months for pneumonitis, 3-5 years for fibrosis or rectal bleeding). Conversely, in children
where growth and development still occurs at the time of therapy and after, evaluation of late
effects over long periods is considered. Since late effects are appreciated more as they evolve
over time, it is more common to grade the severity (rather than the yes/no occurrence) of the
events in children. Thus, this dimension of time also increases the challenge in the study of
late effects. Since it may take years to decades for late effects to manifest in children, detailed
follow-up is critical to assess their severity. Though it is assumed that normal tissue effects in
adult patients remain stable beyond the typical five years of follow-up, studies of potentially
longer-term changes are typically not available.
Patient age and vulnerability—The patient’s age at the time of RT is critical in children.
In general, younger children are more at risk for late effects than older children. Neurocognitive
effects, development of muscles, and growth of bones all are very sensitive to the age at
treatment. Each of these tissues has an age range for development and growth, with some inter-
patient variation. Though age can be integrated into the study and modeling of the effects of
RT, the addition age as a variable further divides this already-small population into subgroups
that lack power for statistical analysis. In contrast, this effect of age is less of an issue in adults
because tissue response does not change as much as a function of age, despite the large spectrum
of patient ages studied.
Statistical feasibility—The population size for the investigation of late effects in adults and
children are different. Late effect studies in adults often benefit from large sample sizes due to
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the large number of available irradiated adults. Indeed, the relatively low incidence of severe
radiation-related effects in adults necessitates large data sets to establish causative factors. For
pediatric patients this situation is reversed; the incidence of malignancies requiring RT for cure
is lower, yet the frequency in which measurable late effects occurs is higher. This relatively
high event rate makes it possible to correlate these effects with treatment parameters and other
clinical variables, despite limited numbers, yielding meaningful analyses. Table 1 summarizes
the general differences in the occurrence and study of late effects between children and adults.
SPECIFIC EXAMPLES OF LATE EFFECTS
Pulmonary effects of radiation therapy
RT-related lung effects, including pneumonitis (RP) and fibrosis (RF), are a major dose-
limiting factor for thoracic RT in both adults and children. In adults and children, predisposing
factors may effect the risk of pneumonitis and fibrosis (e.g. smoking and related chronic
emphysema, pneumonia, asthma) (1,2,3). These predisposing factors and the context of RT
(e.g. conformal lung RT, total body RT) all interact to increase or decrease the subsequent risk
of RP. Table 2 demonstrates general differences between children and adults in the
development and study of RT-induced lung injury.
Clinical scenarios necessitating radiation adjacent to or in the lung—The context
in which the lung receives RT differs between adults and kids. The majority of adults receiving
thoracic RT have lung cancer, while the remainder have cancer in adjacent organs (e.g.
mediastinal lymph nodes, breast, esophagus). Radiation doses are usually non-uniform and
risks are often evaluated via dose volume histograms. Children often receive RT to the lung
primarily in the context of whole lung RT (e.g. metastatic Wilm’s or Ewings) where dose
volume histograms are less useful. The lung is less-often exposed as an adjacent normal tissue
(e.g. mediastinal radiation), though certainly this occurs in the setting of Hodgkin lymphoma
and sarcoma.
Risk and predictors of radiation pneumonitis—Dosimetric factors are the mainstay of
analysis for RP. An array of dosimetric parameters including mean lung dose (MLD) and
volume of lung receiving dose above a certain threshold (e.g. V20Gy) are most commonly used
to predict RP risk in children and adults. Despite extensive analyses, no one parameter is
uniformly predictive across the multiple patient datasets and disease sites and age groups (4).
In adults the incidence of RP ranges widely; from ≈ 3% in adults managed with combined
modality therapy (CMT) for Hodgkin’s disease, to ≈ 5% in patients receiving radiation for
breast cancer, to ≈ 15-44% in some patients irradiated for lung cancer (5-9). In children, the
overall rate of RP for most diseases near the chest remains at the lower end of this spectrum
(10-11). Available data suggests that less that 5% of patients with sarcoma adjacent to the lung
and less than 10% of patients with Hodgkin’s disease receiving CMT will experience clinical
RP.
Diagnosis of radiation pneumonitis—There are differences in the certainty of the
diagnosis for RT-associated lung injury. In adults, the symptom-based diagnosis of RP often
appears in the context of confounding medical problems. Approximately 28% of adult cases
of RP occur with concurrent illness (e.g. cardiac arrhythmia, COPD, pulmonary embolism),
making the diagnosis somewhat uncertain (2). In contrast, children rarely have concurrent
chronic pulmonary problems. Occasionally, acute pneumonia may complicate the diagnosis/
treatment of RP in children, but its response to antibiotics versus steroids usually helps clarify
the diagnosis.
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Studies of predictive models for lung injury—The definition of high-risk dosimetric
parameters has been the primary method for stratifying RP risk in adult patients with lung
cancer, derived from large, well-analyzed dosimetric datasets. MLD, volume of lung >20-30
Gy, and normal tissue complication probability (TCP) models, all correlate with rates of RP
(4,7-9). These parameters still lack high predictive value, as 46-71% of patients with “high
risk” dosimetric parameters do not experience RP, and 7-16% of “low-moderate risk” patients
do experience clinically-significant RP (7,9). In children and young adults, there have been
fewer attempts to correlate dosimetric parameters and RP risk. When dosimetric and clinical
outcome data are available, the overall risk of RP is low at approximately 6%, and rarely >grade
2 in patients receiving non-total body irradiation (10,11). Adult models such as V20Gy ≥ 35%
or MLD > 16 Gy select patients at higher risk for grade 2 pneumonitis in this pediatric cohort
of sarcoma and Hodgkin’s disease patients, but the overall incidence is low and the non-
specificity of these models mimics the experience seen in the adult population (4,7-9,11,12).
Even the application of more complex TCP models to the pediatric RP population did not
improve predictability (10,11). When using MLD as a single dosimetric parameter one can see
the similar broad range of risk predicted for adults and children (data from St. Jude Children’s
Research Hospital {SJCRH} and adult centers – Fig. 1) (13, Personal communication M.
Krasin 2009). This is not to suggest that dosimetric analysis of RP is fruitless; to the contrary
these analyses suggest that dosimetric approaches are important, but are not ideal predictors
alone.
Incorporating clinical, laboratory, and functional parameters into models may improve the
predictive abilities of current dosimetry-only models. In adults receiving total body radiation,
lung dose is the major factor predictive for RP. Assessing for concurrent cytomegalovirus
infection enhances the predictions based on dose alone. (14). In non-smokers age > 59 years
receiving RT for breast cancer, the risk of RP was elevated (15). Active smoking has been
implicated by others to provide a slight protective benefit, possibly related to immune
suppression (1). In 606 patients with breast and esophageal carcinoma, the incidence of RP for
smokers compared to non-smokers was 0.4% vs. 3.6% (p=0.022) (16). These clinical findings
suggest a role for inflammatory cascades in the initiation and development of RP for adult
patients.
Based on the role of inflammation in the pathogenesis of RP, serum cytokine levels of TGF-
beta, IL-1, and IL-6 have been implicated as both predictors and possible mediators for
development of pneumonitis and subsequent fibrosis (17-19). It is hoped that these biomarkers
may enhance predictability and elucidate some of the underlying biology. However, their
ability to add refinement to dosimetric variables is not universally validated (15,17,20).
Incorporating functional-based parameters (e.g. perfusion weighted lung dose and diffusion
capacity) into predictive models may slightly improve their predictive ability for RP over single
parameter dosimetric models alone (21). Functional information from early post-radiation
FDG-PET imaging combined with MLD also correlated with varying grades of RP (some
clinically symptomatic and some only radiographic) though identification after delivery of
radiation was complete reduces its value for prediction (22). Integration of spatial information,
describing dose to the geometrically defined upper and lower lung, improved upon traditional
DVH-based parameters in predicting grade ≥3 RP (23).
In contrast, attempts to integrate factors beyond typical conformal dosimetry in pediatric
patients are more limited. Covariates such as chemotherapy have been analyzed in the context
of patients receiving RT for Hodgkin’s disease. When pre-radiation bleomycin was added as
a covariate to V24Gy in 99 patients analyzed for risk subsequent RP (any symptomatic grade),
the ability to predict risk was significantly increased (Fig. 2), though the absolute risk remained
low (10, Personal communication M. Krasin 2009).
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Risk and predictors of radiation fibrosis—RF is a long-term, often permanent, toxicity
of RT. Despite the extensive analyses of RP in the adult lung cancer population, modern
analyses of dosimetric parameters relative to RF are less common, likely due to the poor
survivorship of the lung cancer population (24). In contrast, patient studies of breast cancer,
Hodgkin’s disease, and particularly pediatric cancer have focused on RF. The surrogates for
radiation fibrosis are either clinical symptoms or findings on pulmonary function testing (PFT).
Long-term outcome data from the Childhood Cancer Survivor Study (CCSS) demonstrates
that children receiving chest RT (including mediastinal, whole lung, and total body irradiation)
had a significantly increased rate of reporting lung fibrosis, chronic cough, dyspnea on exertion,
pleurisy, and the need for supplemental oxygen 5 years or more after diagnosis. The cumulative
incidence of lung fibrosis continued to increase out to >5% at 25 years. Similar findings were
noted for chronic cough (>10% at 25 years), pleurisy (>6% at 25 years) and dyspnea on exertion
(>15% at 25 years) (25). This symptom-specific study, while not addressing the pathobiology
or mechanism for late pulmonary effects in children, does highlight the specific issues faced
by long-term survivors and how these issues affect quality of life on a daily basis. Interestingly,
reported lung fibrosis and pleurisy was more common in patients diagnosed at age >15 years
compared to patients age ≤5 years, counter to what one would expect based on age of
development of the lung and growth of the chest wall; RT dose/volume details are not reported
in these subgroups. In comparison to this experience, limited data are available on long-term
clinical outcomes relating to RF in adults.
Pulmonary function as measured by PFTs has been the most frequently utilized assessment
tool in evaluating long-term lung injury, essentially assessing the degree of RF. Analysis of
PFTs in children following mediastinal RT indicates a pattern of reduction in FEV1 and DLCO
compared to non-RT controls (26). In this same study, residual volume was also reduced,
possibly a restrictive deficit related to loss of compliance in an irradiated chest wall. Children
receiving whole lung RT have a similar restrictive pattern with reductions in FEV1/FVC ratios
and total lung capacity (27). Young age was not correlated to the severity of the deficits seen.
Adult studies almost universally report a drop in normalized PFT values (forced expiratory
volume in one second (FEV1), forced vital capacity (FVC) and diffusion capacity for carbon
monoxide (DLCO)) ≈ 3 months post-RT (6,28). Some authors report a partial recovery of lung
injury between 3-18 months, representing some compensatory mechanism of remaining
functional lung or recovery from early damage (6,29). Others, notably in patients treated for
lung cancer, found no stabilization and rather continued decline in these parameters. PFT
declines over time are shown in figure 3 (6,28,30).
Imaging may serve as a surrogate metric for fibrosis. Only adult studies have assessed changes
in regional perfusion following thoracic RT. Loss of SPECT-defined perfusion evolves during
the first 3-12 months post-RT, and stabilizes thereafter. CT defined density changes in the lung
also progress over time relative to dose (31). However, there is no clear association between
these perfusion abnormalities and changes in patient’s symptoms or PFTs (32,33).
RF and late pulmonary effects remain a complex constellation of late effects incorporating
alterations involving the pulmonary parenchyma, associated changes in spirometry, chest wall
dysfunction, and respiratory symptoms. For pediatric patients, integration of dosimetry,
functional imaging and detailed study of chest wall dysfunction is needed. Participation by
radiation oncologists in the design of long-term studies incorporating baseline measurements
would increase understanding. Adults stand to benefit by incorporating the long-term follow-
up approach developed in the CCSS. Understanding how quality of life is affected beyond 5
years could support or alter RT treatment strategies currently in use. Newer trials have already
begun to remedy some of these deficiencies, incorporating conformal radiation dosimetry,
toxicity monitoring and detailed follow-up (34).
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Skeletal effects of radiation therapy
Bone, in contrast to lung, is less frequently considered as a dose limiting normal tissue,
particularly in adults. In children, this concern is reversed; bone and its potential growth drive
heated discussions at tumor boards and require lengthy consent consultations with families.
The spectrum of toxicities also differs across the age range and includes fracture,
osteoradionecrosis, and growth retardation (table 3).
Clinical scenarios necessitating radiation to the bone—Most RT treatment fields in
both children and adults include incidental irradiation of bone. There are several regions of
treatment for which special consideration is given to bone. The mandible for adult patients is
considered vulnerable due to its limited blood supply, essential function, and risk from RT
doses as high as 70 Gy delivered in its proximity. Weight bearing bones also deserve particular
consideration as necrosis or fracture could be debilitating. Alterations in growth are a concern
in younger pediatric patients where RT is delivered to growing bone. Despite the diversity of
sites and toxicities, the mechanisms of bone growth, maintenance, and injury share common
features across the skeletal system in adults and children.
Osteoradionecrosis—Osteoradionecrosis (ORN) of the mandible, initially described in
1920, remains a consideration in adults receiving high dose RT (35). ORN is also seen in the
maxilla and described in the sacrum (36,37). The cumulative incidence of mandibular ORN in
adults with head and neck cancer ranges from 3 - 8% (38-40). ORN often occurs within two
years of RT, particularly in the head and neck region when RT is delivered prior to or absent
surgery (39,40). When RT is delivered following surgery, or in the sacral region, ORN may
occur years later (38,39). Its etiology, initially thought to be of relation to vascular
insufficiency, is evolving to include the formation of fibrosis and atrophy. Osteonecrosis of
the mandible and maxilla in patients receiving bisphosphonates suggest that inhibition of
osteoclast activity also plays a role in ORN (41,42). Clinical factors associated with its
formation include dental extractions, mandibular surgery, trauma to the mucosa, and higher
effective radiation dose (36,39,40). In the modern era, application of IMRT and other
conformal techniques have reduced the incidence of ORN (1 in 73 “at risk” patients), felt to
be primarily related to reductions in mandibular volume receiving high dose RT (43). Though
a reduction in incidence may be achieved through application of modern techniques,
management options for ORN are limited. Hyperbaric oxygen, thought to improve oxygenation
in poorly vascularized tissue, was not found to be beneficial in a randomized controlled trial
of patients with ORN (44). Conservative clinical management incorporating antibiotics and
subsequent surgery remains the mainstay of treatment for ORN, though only about one-third
of patients with mandibular involvement have complete healing (36,37). Though a significant
and long standing body of work regarding ORN exists for adults, little data is available
regarding children. Prophylaxis with hyperbaric oxygen is standard when dental extractions
are needed following high dose (~60 Gy) mandibular RT. Data to support or refute this
approach is lacking and studies defining the incidence and prognostic factors of ORN in
children are not available.
Fracture—RT-associated fractures are a risk for both adults and children (Fig. 4). The
cumulative incidence varies based on the population studied, ranging from <10% to >23% in
children (45,46). In an institutional series of pediatric patients receiving RT for
rhabdomyosarcoma, non-rhabdomyosarcoma soft-tissue sarcomas, and Ewing’s sarcoma, the
overall 4 year cumulative incidence of fracture was 10% (Fig. 5) and was elevated to 29% in
weight bearing bones (Personal communication M. Krasin 2009). A similar 31% rate of fracture
was reported in a series of patients with Ewing’s sarcoma undergoing RT to weight bearing
bones (45). Fractionation also influenced risk in this study. Estimates for fracture in adults
following RT also vary, but range from 4% to 29% in those with periosteal excision in addition
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to RT. Reported etiologies include prior occurrence of ORN, RT to a weight bearing bone, and
additional trauma or surgery (47,48). Factors such as periosteal excision or stripping increase
the rate of subsequent fracture (??by) 29% (49,50). Dosimetrically, mean dose and maximum
dose to 2cc of bone and V40Gy for bone all predict patients at higher risk for fracture; however,
the absolute magnitude of the increased risk in patients with unfavorable dosimetric parameters
is a modest 10%, thus a RR 1.1. This suggests that such dosimetric factors are sub-optimal
predictors of a truly high risk group (51). Though not frequently discussed as a normal tissue
for avoidance, the incidence of fracture for certain subpopulations of adults and children is
substantial and suggests that a greater understanding of the underlying clinical factors,
dosimetry and biology are needed.
Bone growth—Alterations in bone growth are common considerations in the pediatric age
group. This is not a concern in adults. It presents slowly, but can result in dramatic alteration
in bone length and volume as well as associated muscle hypoplasia (Fig. 6). Understanding the
etiology of these alterations has been a long standing pursuit (42-54). Many models to describe
bone growth have been multi-factorial, and include age, bone location and type, volume of
bone irradiated, and RT dose (55-57). Alteration in vasculature and chondrocyte populations
are suspected as the biologic basis of RT’s effect on bone length and bone volume, resulting
in facial asymmetry, extremity shortening, clavicular shortening, reduced sitting height, and
long bone asymmetry (53,55,56,58-60). Growth of flat bones, including the facial bones,
clavicle, and pelvis has been correlated with dosimetric and clinical endpoints. Multiple
threshold doses have been considered with the most obvious and significant loses of bone
growth occurring in patients receiving higher doses and larger volumes of treatment. Models
suggest that a significant volume of flat bone growth may be lost as the integral dose >35 Gy
delivered to bone increases (57). Age is a highly significant covariate, and children <5 years
of age experienced statistically greater bone loss than that of older children, as anticipated.
Though the magnitude of flat bone growth loss is greatest in the youngest children, this study
and others note that growth loss is continuous. When examined closely, even older patients
and those receiving lower doses of RT will have some reduction in bone growth over time
(55,57,60). This continuous effect is also noted for long bones and can be seen by clinically
measuring stature compared to normative data, vertebral height across 2 dose groups, or long
bone length (46,55,57,61). Though a continuous relationship between bone growth loss, dose,
and age may be defined, it is worthwhile to consider thresholds in the context of RT planning
to at least provide a goal for normal tissue avoidance. Doses ≥15 Gy, particularly those >30
Gy, appear to result in the most clinically measurable effects.
Little clinical work has been published that describes the biologic events responsible for
changes in bone growth. Changes to the epi??physis including widening of the growth plate
and formation of a metaphyseal line are noted on plain radiographs following radiation to the ?
e[iphysis (53). Alterations in bone growth were not uniformly seen with radiation doses >39
Gy and subsequent abnormal findings in the ?epiphysis, suggesting that a process of repair
may occur in some patients. Normal growth plate biology incorporates endocrine and paracrine
signaling of chondrocytes, angiogenesis, and modeling and remodeling of the extracellular
matrix. These processes are disrupted by RT, the latter which was originally thought to be a
permanent alteration but may be reversible. Animal experiments suggest that chondrocytes
exhibit some degree of restoration following single fraction and fractionated radiation (62,
63). This restoration of function, as well as evidence that melatonin may provide a protective
effect on the ?epiphysis in rats, indicates that better understanding of the biology of the process
would not only improve our ability to predict patients and dosimetric features at high risk for
growth loss, but also may provide targets for prophylaxis in those patients requiring RT to the
bone (64).
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Clinical, dosimetric and biologic investigations of RT-related normal tissue effects in adults
and children remain an important area of research. Frequently relying on input from our physics
and biology colleagues, we incorporate variables and methods to enhance our understanding
of these tissue effects. Integration of measurable endpoints, derived from collaborations with
pediatric or adult medical oncologists and other sub-specialists, allow us to design clinical trials
and research studies to identify treatment effects, their severity and the degree to which they
affect our patients. The examples given here, lung and bone, are indeed just examples. Similar
discussions could have been presented for other organs. Understanding the skeletal and
pulmonary effects of RT in adults and children is important for the care of our patients and
design of clinical trials, yet on a more basic level these two tissue systems demonstrate what
is good and bad about our approaches to normal tissue research across the age spectrum. To
further the progress we have made, age must no longer create a barrier for discussion, but
should comprise a variable for study. Meetings, journals, and other forums must accept that
pediatrics and adults often should be discussed together, not apart, when normal tissues are
concerned. Our progress and our patients will both benefit when we look across the ages and
borrow from those that are younger or older.
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MLD plotted against pneumonitis risk in adults and children.
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Probability of symptomatic radiation pneumonitis for 99 patients with Hodgkin’s disease
receiving radiation with or without bleomycin based on percent volume of total lung irradiated
above 24 Gy
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Trends for pulmonary function studies following radiation therapy to the chest in adult patients.
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Dosimetry, fracture and subsequent repair and healing of a femoral fracture following a cart-
wheel in a child managed with radiation therapy to the thigh for rhabdomyosarcoma.
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Cumulative incidence of fractures in a clinical trial of 129 pediatric and young adult patients
receiving radiation therapy for soft-tissue and bone sarcomas.
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A long term survivor of whole-bone radiation for Ewing’s sarcoma demonstrating limb
shortening, volume loss and hypoplasia.
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Table 1
General comparison of late effects between children and adults.
Aspects of late effects Children Adults
Incidence of cancer (Population
at Risk)
Low High
Classification of late effects Evolving over time Binary
Likelihood of some measurable
late effect
High (~75-100%) Variable (~20-50%)
Importance of age at RT Critical Limited
Ability to accurately quantify
the risk
Poor, small numbers, limited
statistical power
Good, large numbers, adequate
statistics, limited by follow-up and
competing risks of death
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Table 2
RT-associated lung injury in children and adults.
Aspects of RT-associated lung injury Children Adults
Common endpoints Radiation fibrosis,
alterations in PFTs
Radiation pneumonitis
Pre-existing lung disease Uncommon Very common
Effect of pre-existing lung disease on risk
of RT-associated lung injury
Minimal Moderate
Presence of cancer in the lung itself Rare – adjacent tumors Common
Diagnostic certainty of lung injury’s
relation to RT
High Moderate – at times very unclear due to
comorbid conditions
Underlying pathology More frequent restrictive
deficits
Parenchymal injury limiting perfusion
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Table 3
RT-associated skeletal injury in children and adults.
Aspects of RT-associated skeletal injury Children Adults
General concern during RT planning High Low
Primary issue Growth Necrosis, fracture
Effect of pre-existing lung disease on risk of
RT-associated lung injury
Minimal Moderate
Dose limit Low ~ 30 Gy High ~ 60 Gy +
Bone at risk Any Mandible, weight bearing (i.e.
femur)
Common clinical scenarios Craniospinal irradiation, RT
for sarcomas
Head & neck cancer, prostate
cancer
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